

Appendix H: Issued US patents which include claims drawn to antibodies defined by a single CDR domain

#	Inventor	Patent No.	Claims / Comments
1	Reiter <i>et al.</i>	6,951,646 B1	Claim 1: An isolated antibody comprising at least the VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO:4, which antibody specifically recognizes a conformation-dependent epitope of Hepatitis C Virus (HCV) glycoprotein E2 and precipitates covalently or non-covalently associated E2/E1 complexes.
			Claim 4: The isolated antibody of claim 1 comprising the VH amino acid sequence SEQ ID NO:4.
2	Salfeld <i>et al.</i>	6,914,128 B1	Claim 16: An isolated human antibody, or an antigen-binding portion thereof, which: a) inhibits phytohemagglutinin blast proliferation in an vitro PHA assay with an IC ₅₀ of 1×10^{-9} M or less; b) has a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 25; and c) has a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 26.
3	Salfeld <i>et al.</i>	6,090,382	Claim 9: An isolated human antibody, or antigen-binding portion thereof, with the following characteristics: a) dissociates from human TNF α with a K _{off} rate constant of 1×10^{-3} s ⁻¹ or less, as determined by surface plasmon resonance; b) has a light chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 3, or modified from SEQ ID NO: 3 by a single alanine substitution at position 1, 4, 5, 7 or 8 or by one to five conservative amino acid substitutions at positions 1, 3, 4, 6, 7, 8 and/or 9; c) has a heavy chain CDR3 domain comprising the amino acid sequence of SEQ ID NO: 4, or modified from SEQ ID NO: 4 by a single alanine substitution at position 2, 3, 4, 5, 6, 8, 9, 10 or 11 or by one to five conservative amino acid substitutions at positions 2, 3, 4, 5, 6, 8, 9, 10, 11 and/or 12.

4	Young <i>et al.</i>	6,818,216 B2	<p>Claim 3: An isolated antibody comprising a VL complementarity determining region (CDR) 1 having an amino acid sequence of SEQ ID NO:39, wherein the antibody immunospecifically binds to a RSV antigen.</p> <p>Claim 1: An isolated antibody comprising a variable light (VL) domain having an amino acid sequence of SEQ ID NO:11, wherein the antibody immunospecifically binds to a respiratory syncytial virus (RSV) antigen.</p>
5	Burton <i>et al.</i>	6,156,313	<p>Claim 1: A human monoclonal antibody which neutralizes both Herpes simplex virus (HSV) Type 1 and Type 2, binds to an epitope present on glycoprotein D, has the binding specificity of an Fab fragment produced by ATCC 69522, and has heavy chains with a CDR of SEQ ID NO:1.</p> <p>Note: SEQUENCE ID NO 1 is the amino acid sequence for the CDR3 region of the heavy chain of clone FabHSV 8.</p>
6	Williams <i>et al.</i>	6,827,925	<p>Claim 1: An antibody comprising a specific binding member capable of binding an intracellular antigen, wherein said specific binding member comprises a polypeptide binding domain comprising an amino acid sequence as set out as residues 99 to 106 of SEQ ID NO: 2.</p>
7	Courtenay-Luck	5,833,943	<p>Claim 1: A molecule, comprising the amino acid sequence EPPT (SEQ ID NO:1) and capable of binding mucin, provided that said molecule is not the monoclonal antibody HMFG-2.</p> <p>Claim 2: The molecule according to claim 1, further comprising a variable region of an antibody, said amino acid sequence EPPT (SEQ ID NO:1) being part of a CDR3 of the V_H variable region, provided that said molecule is not the monoclonal antibody HMFG-2.</p>
8	Burton <i>et al.</i>	5,762,905	<p>Claim 1: A human monoclonal antibody that neutralizes both antigenic subgroup A and subgroup B of respiratory syncytial virus (RSV), wherein the antibody binds to an epitope present on glycoprotein F, and has the binding specificity of the antibody Fab fragment produced by ATCC 69702.</p>

			<p>Claim 2: The human monoclonal antibody of claim 1, which is an Fab fragment.</p> <p>Claim 3: The human monoclonal antibody of claim 1, wherein the heavy chain comprises a CDR3 polypeptide sequence selected from the group consisting of: APIAPPYFDH (SEQ. I.D. 1).</p>
9	Kimachi <i>et al.</i>	5,760,185	<p>Claim 1: A felinized chimeric antibody having a heavy chain variable region (VH) and a light chain variable region (VL) obtained from a murine antibody, which specifically reacts with feline herpes virus-1 (FHV-1) and has a neutralizing activity against FHV-1, wherein the amino acid sequence of one of the complementarity determining regions (CDRs) of heavy chain variable region (VH) has the amino acid sequence Asp Gly Ala Trp Phe Pro Phe (corresponding to amino acid residues 126 to 132 of SEQ ID NO:2) and the amino acid sequences of the constant (C) regions of the heavy (H) and light (L) chains are those obtained from a feline antibody.</p>